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Infectious diseases remain an important global health problem. The interaction of a wide
range of pathogen bacteria with host cells from many different tissues is frequently
mediated by proteoglycans. These compounds are ubiquitous complex molecules
which are not only involved in adherence and colonization, but can also participate
in other steps of pathogenesis. To overcome the problem of microbial resistance to
antibiotics new therapeutic agents could be developed based on the characteristics of
the interaction of pathogens with proteoglycans.
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INTRODUCTION
According to the World Health Organization (WHO), in high-income countries people
predominantly die of chronic diseases, whereas infectious diseases in low-income countries cause
almost one third of all deaths (World Health Organization, 2014b). It is necessary to focus research
not only on currently non-controlled infectious pathologies, but also on those pathogens which
have hitherto been considered controlled in high income countries but are now re-emerging, as
well as newly emerging diseases. One of the most important reasons behind the emergence or re-
emergence of a disease is the fact that most such pathogens are able to evolve quickly, thus acquiring
transmissible genetic modifications that give them an advantage in overcoming both the host and
environmental changes, as in the case of the evolution and the transference of antibiotic resistance
genes in current generation of drug-resistant strains of bacteria. The spread of these resistant strains
is favored by both global trade and the mobility of individuals, resulting in infectious diseases
becoming a global health problem (Morens and Fauci, 2013). The report “Antimicrobial resistance:
global report on surveillance,” published by the WHO in April 2014 and based on data from 114
countries worldwide, highlights the problem of the large increase in antimicrobial resistance in
all regions of the world (World Health Organization, 2014a). Among other things, the WHO has
drawn attention to the need to develop new diagnostic products, antibiotics and other instruments
that allow health professional to combat emerging resistances.
Bacterial adherence and colonization of host cells are the crucial initial steps for infection
to occur. Innovative strategies of interference in bacterial adhesion need to be considered and
developed by investigating the mechanisms used by bacteria to overcome host defenses and attach
to host cells. Bacteria possess diverse adherence mechanisms, including pili, fimbriae and various
types of membrane proteins, all of which can exist in the same pathogen and co-operate to increase
bacterial adhesion (Virji, 2009).
An interesting feature of the molecules used as receptors by pathogens is their wide distribution
in tissues, while simultaneously presenting a certain degree of variability that enables the tropism
known to exist in some bacterial adhesions. Proteoglycans (PGs) meet both these conditions; they
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are complex ubiquitous molecules which have a different
distribution and composition depending on the tissue (Esko
et al., 2009). PGs consist of different types of core protein
modified with chains of anionic polysaccharides called
glycosaminoglycans (GAGs). GAGs are mainly made up of
repeated disaccharide units, and depending on the composition
of these units they can be classified as either: heparin/heparan
sulfate (HP/HS), chondroitin/dermatan sulfate (CS/DS), keratan
sulfate, and hyaluronic acid (HA; Esko et al., 2009; Figure 1).
HS, composed of glucuronic acid and N-acetyl glucosamine,
is the most widespread and physiologically relevant GAG
(Sugahara and Kitagawa, 2002). It has a complex biosynthesis:
after the polymerization of the sugar backbone, the chains
are modified in different interdependent reactions, including
N-deacetylation/N-sulfatation, epimerization, and various
O-sulfations. This modification process is carried out by a
number of correlated enzymes which act in a certain order. The
first reaction, N-deacetylation/N-sulfatation, generates a domain
organization of HS chains that includes N-acetylated (NA)
and N-sulfated (NS) domains, which are separated by mixed
NA/NS domains. Most subsequent modifications take place in
NS domains, which become highly modified and hypervariable
(Sugahara and Kitagawa, 2002). It has been described that
NA/NS domain length and NS domain sulfation patterns are
characteristic of the type of cell involved, and on its physiological
state (Sugahara and Kitagawa, 2002; Figure 2).
Proteoglycans with HS moieties (HSPGs) can be classified
according to their location: on the cell surface, where two families
are found: the transmembrane syndecans and the glycosyl
phosphatidylinositol-anchored glypicans; in the extracellular
matrix (ECM) where there are three types of HSPGs: agrin,
perlecan and type XVIII collagen; and inside intracellular
vesicles, where serglycin is located (Sarrazin et al., 2011;
Table 1). HSPGs have multiple functions, some of them
dependant on the core proteins, but most related with the
GAG chains because of their characteristic epimerization and
sulfation pattern. This structural diversity allows HSPGs to
FIGURE 1 | Repeating disaccharide units of GAGs.
FIGURE 2 | Heparan sulfate (HS) domain architecture. The highly
sulfated NS-domains are flanked on either side by less-sulfated transition
zones (NA/NS). In turn, these sulphated regions are separated by
non-sulfated NA-domains.
play a key role in many processes including cell adhesion and
migration, organization of ECM, regulation of proliferation,
differentiation and morphogenesis, cytoskeleton organization,
tissue repair and inflammation. HSPGs can bind several
ligands such as cytokines, chemokines, growth factors, and
morphogens, protecting them against proteolysis and controlling
their gradients (Sarrazin et al., 2011). HSPGs co-operate with
different molecules to define basement membrane structure and
to mediate in cell-ECM attachment, cell–cell interactions, and
cell motility (Sarrazin et al., 2011). Shedding of membrane-
bound HSPG ectodomains can be carried out by enzymatic
cleavage (Garton et al., 2006; Nam and Park, 2012; Figure 3),
and is an important factor in host response to tissue injury
and inflammation in pathophysiological processes (Garton et al.,
2006).
HS moieties are involved in the adherence of many
microorganisms. This ranges from attaching normal human
microbiota to cell surfaces and includes the genus Lactobacillus,
which interacts primarily with HS and CS in the vaginal and
intestinal epithelium (Martín et al., 2013), to various pathogenic
bacteria, viruses, and parasites. Pathogens interact with HPSGs
not only to achieve adherence and colonization, but also in
invasion, internalization, dissemination, and toxicity (Kamhi
et al., 2013; García et al., 2014). Some bacterial pathogens are
even able to induce shedding of cell surface HSPGs, particularly
syndecan-1. The released syndecan-1 ectodomain then binds
to host defense factors, such as antimicrobial peptides and
cytokines, which then become inhibited in a HS-dependent
manner, resulting in deregulation of the infection response and
the promotion of pathogenesis (Menozzi et al., 2002; Barlett and
Park, 2010).
This review focuses on describing the role of PGs and GAGs
in the principal human infectious diseases caused by bacteria
(Table 2).
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TABLE 1 | Classification of HSPGs according to their location.
Heparan sulfate proteoglycans
Cell surface Transmembrane syndecans
Glycosylphosphatidylinositol-anchored
glypicans
Extracelullar matrix Agrin
Perlecan
Type XVIII collagen
Intracellular vesicles Serglycin
FIGURE 3 | Adhesion of bacterium to target cells mediated by HS and
shedding of syndecan ectodomains. Schematic representation of the
interaction between an adhesin on the outer membrane of a Gram negative
bacteria and HS from syndecan on the cell surface of a eukaryotic.
INFECTIOUS RESPIRATORY DISEASES
Common upper respiratory infections include the common
cold, tonsillitis, pharyngitis, epiglottitis, and laryngotracheitis.
Infections of the lower respiratory tract include bronchitis,
bronchiolitis, tuberculosis, and pneumonia. Flu may affect either
the upper or lower respiratory tract (Dasaraju and Liu, 1996). The
WHO states that the leading infectious cause of death is lower
respiratory infections, which caused more than 3 million deaths
worldwide in 2012 (World Health Organization, 2014b).
Pneumonia, one of the most common lower respiratory
infections, is an inflammation of the lung parenchyma,
commonly caused by viruses or bacteria when the functioning of
the host’s immune system is reduced.
The most frequent type of pneumonia is caused by
streptococci, particularly by Streptococcus pneumoniae. This
bacterium is also a significant cause of meningitis, bacteremia,
and otitis media (Tuomanen et al., 1987; Hollingshead and Briles,
2001). During the colonization step, S. pneumoniae binds to
mucosal epithelial cells using HS and CS as receptors (Tonnaer
et al., 2006). Additionally, the pathogen produces extracellular
glycosidases which modify various glycans and GAGs in the
human airway epithelium and, as a consequence, more receptors
for adherence are revealed, and the sugars released are used
by the pneumococci for growth. The glycosidases secreted
also negatively affect other bacteria, giving the pathogen an
advantage in interspecies competition (King, 2010). Furthermore,
S. pneumoniae has the ability to induce the ectodomain shedding
of syndecan-1 from the cell surface. In fact the TIGR4 strain
directly stimulates shedding through a ZmpC metalloproteinase
in an intracellular signaling-independent manner in order to
promote its pathogenesis. However, other strains do not express
ZmpC and they shed syndcan-1 through an as yet unknown
alternative mechanism (Chen et al., 2007).
Haemophilus influenzae constitutes the second most common
cause of bacterial pneumonia. Strains of this bacterium are
classified into typeable and non-typeable (NTHi), depending on
the presence or absence, respectively, of a polysaccharide capsule
(King, 2012). NTHi strains are the main cause of infections in the
respiratory tract, affecting mainly non-ciliated cells or damaged
mucosa (King, 2012). NTHi has several different mechanisms
for adherence to mucosal surfaces, e.g., five types of pili and
a large number of surface proteins, including diverse adhesins
such as protein E, Hia, Hap, and protein F (Moulder, 1991).
Approximately 75% of NTHi strains express the adhesins HMW1
and 2 (high molecular weight proteins 1 and 2), which bind to
sulfated GAGs, particularly to HS chains (Finney et al., 2014).
NTHi can undergo phase variation to promote the persistence of
bacteria (Noel et al., 1994).
Another causative agent of bacterial pneumonia is the obligate
intracellular human pathogen Chlamydia pneumoniae. This
microorganism has a unique biphasic life cycle with two forms,
the elementary bodies (EBs) and reticulate bodies (RBs). EBs are
responsible for infecting host cells and promoting entry, after
which they transform into RBs. This intracellular RB form uses
the host metabolism to replicate and reorganize itself back into
EBs, which are then released into the lung by cell lysis and enable
the infection of new cells (Moulder, 1991). The initial attachment
of EBs to the epithelium surface is mediated by HS chains, mainly
through electrostatic interactions, although other co-receptors
may be required for efficient attachment and entry (García et al.,
2014).
Another important infection of the lower respiratory tract is
tuberculosis. According to the WHO, this disease is the second
leading cause of death attributable to a single infectious agent
(World Health Organization, 2015). The infection commonly
begins in the lungs but can spread to other tissues through
the expression of a heparin-binding protein (Chen et al., 2008).
Mycobacterium tuberculosis adheres to pulmonary epithelial cells,
although the microorganism is also able to infect phagocytes. The
bacteria’s adherence to the epithelium is mediated predominantly
by heparin-binding hemagglutinin adhesin (HBHA), which
interacts with HS chains. HBHA also mediates in the triggering
mechanisms for the transcytosis process, which leads to
extrapulmonary dissemination of the infection (Menozzi et al.,
2006; García et al., 2014).
The microorganism Pseudomonas aeruginosa is an
opportunistic pathogen that is, among other diverse infections,
the major cause of burn infections and cystic fibrosis (CF). This
bacterium uses diverse strategies, which may act independently or
in combination, including type IV pili and adhesins, to produce
a wide range of infections (Barlett and Park, 2011). The pathogen
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needs an injured respiratory epithelium in order to bind properly
as such damage affects the tight junctions between epithelial cells
and leaves the basolateral receptors exposed (Barlett and Park,
2011). In polarized cells, P. aeruginosa uses different receptors
depending on the side of the cell involved, binding to complex
N-glycans on the apical surface and to HS moieties of HSPGs on
the basolateral surface (Barlett and Park, 2011). During injury
and dedifferentiation of epithelium, cells are not completely
polarized, and levels of HSPGs are increased on the apical
surface. In these circumstances, both HSPGs and N-glycans act
as receptors for the pathogen on the apical surface. Another
strategy employed by P. aeruginosa to increase its pathogenicity
is the virulence factor LasA, a zync metalloendopeptidase, which
is able to induce syndecan-1 shedding indirectly (Barlett and
Park, 2011). This shedding downregulates the host defenses,
leading to increased bacterial virulence and enhances its survival
(Chen et al., 2008). Circulating GAG levels in CF patients are
increased, not only due to shedding, but also because of other
TABLE 2 | Diverse infectious pathologies caused by bacteria and mediated
by GAGs, indicating the molecular species involved.
Localization Pathology Bacteria GAGs
Respiratory tract Pneumonia Streptococcus
pneumoniae
HS, CS
Pneumonia Haemophilus
influenzae
HS
Pneumonia Chlamydia
pneumoniae
HS
Tuberculosis Mycobacterium
tuberculosis
HS
Cystic fibrosis Pseudomonas
aeruginosa
HS
Pertussis Bordetella pertussis GAGs
Pharyngitis Streptococcus
pyogenes
HS, DS
Systemic Lyme disease Borrelia burgdorferi HS, DS
Central nervous system Meningitis Streptococcus
agalactiae
GAGs
Meningitis Streptococcus
pneumoniae
HS, CS
Meningitis Neisseria
meningitidis
HS, CS
Gastrointestinal tract Gastritis, ulcers Helicobacter pylori HS
Inflammation Enterococcus
faecalis
HS
Inflammation Streptococcus
agalactiae
HS
Inflammation Staphylococcus
aureus
HS
Listeriosis Listeria
monocytogenes
HS
Urogenital tract Gonorrhea Neisseria
gonorrhoeae
HS
Urogenital
chlamidiasis
Chlamydia
trachomatis
HS, DS
Cornea Keratitis Staphylococcus
aureus
HS
Keratitis, ulcers Pseudomonas
aeruginosa
GAGs
bacterial exoenzymes which are produced to inactivate the
action of molecules from the host immune system. P. aeruginosa
produces proteinases, elastase, and alkaline proteinase all of
which release DS from matrix PG decorin, which then binds
to neutrophil-derived α-defensin, whose bactericidal activity
is thereby neutralized (Schmidtchen et al., 2003; Barlett and
Park, 2010). Released GAGs are also able to interact with LL-37
electrostatically, inhibiting its binding with bacteria and in this
way disabling its bactericidal action. Unconjugated LL-37 peptide
can be degradated through proteolysis by neutrophil elastase and
cathepsin D, which is induced by P. aeruginosa (Kamhi et al.,
2013).
Pertussis is a highly contagious bacterial disease of the
respiratory tract that mainly affects infants and young children.
The WHO estimates that about 16 million cases of pertussis
occurred worldwide in 2008, and it continues to be a public
health concern even in countries with high vaccination coverage
(World Health Organization, 2011). The infection is caused by
Bordetella pertussis, which expresses filamentous hemagglutinin
adhesin (FHA), which binds to sulfated GAGs by its C-terminal
to initiate the infection of bronchial epithelial cells (Hannah et al.,
1994).
The pathogen Streptococcus pyogenes is a member of Group
A streptococci. This microorganism is able to infect different
human tissues, including the respiratory tract. The bacterium
interacts with different GAGs from cells surfaces, mainly with
DS and HS, through different types of protein M, its major
surface-expressed virulence factor (Frick et al., 2003).
SYSTEMIC INFECTION DISEASES
In some infections, the bacterial pathogens are distributed
through multiple tissues. An example is Lyme disease, a
chronic multisystem disorder caused by the obligate intracellular
pathogen Borrelia burgdorferi, in which the skin, heart, joint,
skin, and nervous system may be affected This bacterium has
multiple surface proteins with different binding specificities to
GAGs depending on the tissue affected (Leong et al., 1998).
In addition, different GAGs act as receptors for B. burgdorferi
depending on the host cells; both HP and HS are essential in
adherence to primary endothelium and adult kidney Vero cells,
but only DS is involved in attachment to human embryonic
kidney cells, while all these GAG species mediate adherence to
HeLa cells, neuronal and primary telencephalon cell lines (Leong
et al., 1998; García et al., 2014).
Sepsis is the systemic host response to microbial infections,
and, among other alterations, this involves an increase in the
permeability of the endothelium caused by the shedding of its
PGs (Henrich et al., 2010). Shedding of syndecan-1 is stimulated
by proinflammatory substances and, as a consequence, levels
of circulating syndecan-1 increase, thereby promoting leukocyte
adherence (Nelson et al., 2008). This increase in syndecan-1
levels is correlated with the cardiovascular SOFA (Sequential
Organ Failure Assessment) score. During septic shock there are
high levels of some GAGs in plasma and, although there is
no correlation with syndecan-1 levels, they are correlated with
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mortality (García et al., 2014; Nelson et al., 2014). Specifically, the
quantity of circulating HS and HA increases, while KS levels are
moderately reduced, and those of CS remain unaltered (Nelson
et al., 2014). These released GAGs are mainly from the altered
endothelium, but they can also come from connective tissue and
basement membrane (Nelson et al., 2014).
NERVOUS SYSTEM INFECTIONS
Certain microbes invade brain endothelial cells and breach the
blood–brain barrier (BBB) through interactions with GAGs, thus
establishing central nervous system infections (Chang et al.,
2011).
Meningitis has been declared one of the top 10 causes
of mortal infection worldwide, and is particularly devastating
in newborns (World Health Organization, 2014b). The most
common agent of neonatal bacterial meningitis is Streptococcus
agalactiae, which uses alpha C protein (ACP) to interact
electrostatically with GAGs and cross the BBB. ACP also mediates
streptococci entry into epithelial cells, involving Rho GTPase-
mediated actin polymerization (García et al., 2014). GAG
expression patterns are important for adherence in different cells,
since they determine the efficiency of bacterial dissemination
during infection by S. agalactiae (Chang et al., 2011).
In older children and adults, meningitis is mainly caused by
S. pneumoniae and Neisseria meningitidis. As described above, the
binding of S. pneumoniae to cells happens through interactions
with sulfated GAGs, mainly HS and CS4 (Tonnaer et al., 2006).
The pathogen N. meningitidis has a large number of molecules
involved in adhesion including adhesin OpC, which binds to HS
to initiate epithelial cell invasion (de Vries et al., 1998).
GASTROINTESTINAL INFECTION
DISEASES
More than 1200 bacterial species can inhabit the healthy human
gastrointestinal tract, and there is not yet general agreement on a
reliable total number of species (Rajilic´-Stojanovic´ et al., 2007).
The pathogenic bacterium Helicobacter pylori appears adhered
to human gastric mucosa, and its presence is associated with
chronic gastritis type B and ulcers. What is more, H. pylori
has been found to be related with gastric cancer, and has been
designated a class I carcinogenic agent by the International
Agency for Research on Cancer (García et al., 2014). Different
outer-membrane proteins of H. pylori bind to HS from gastric
cells to bring about adhesion (Guzman-Murillo et al., 2001). The
pathogen also secretes various proteins that also interact with HS
chains, such as cytotoxin vacA. This toxin attaches and enters
into cells inducing vacuolation, which in turn leads to host cell
death (Palframan et al., 2012). The most pathogenic strains of
H. pylori have the cag pathogenicity island, which encodes the
cytotoxic protein CagA, and a type IV secretion system that
injects this protein into the gastric cells (Odenbreit et al., 2000).
Protein CagA affects intracellular signaling pathways, including
the NF-kB pathway, which leads to upregulation of the expression
of the gene encoding syndecan-4, which is commonly found
overexpressed in carcinoma cell lines (Odenbreit et al., 2000).
Some of the species that reside in the human intestinal tract
are typically associated with systemic infection in post-surgical,
shock, and in trauma patients. This is the case of Enterococcus
faecalis, the major cause of nosocomial infections, which affects
a variety of tissues (Baldassarri et al., 2005). Enterococci
use HS for initial adherence and for their internalization in
professional and non-professional phagocytes, which is mediated
by triggering cascades of protein kinases and the reorganization
of microtubules (Kamhi et al., 2013). E. faecalis is able to resist
specific killing mechanisms inside these phagocytes and thus
continue its invasion and dissemination (Baldassarri et al., 2005).
Although syndecan-1 is widely expressed in enterocytes, it has
been proven not to be essentially involved in the adhesion of
any enterococci (Sava et al., 2009). However, it does play a role
in interactions with other enteropathogenic bacteria, such as
Listeria monocytogenes, staphylococci and streptococci, which
may use the intestinal tract as a portal of entry in special
circumstances (Sava et al., 2009).
Listeriosis is a serious infection caused by eating food
contaminated with the intracellular pathogen L. monocytogenes.
The bacterium employs different membrane proteins to adhere
to epithelial cells using HSPGs, particularly syndecan-1 (Henry-
Stanley et al., 2003). L. monocytogenes has great invasive
capacity, thanks to its ability to induce its own internalization
in a wide range of cells (Henry-Stanley et al., 2005). In
phagocytic cells, the bacterial surface protein ActA plays two
important roles: extracellularly, it mediates adhesion by binding
with low affinity to HSPGs; intracellularly, it directs actin
assembly which is needed for the bacterium’s intracellular life-
cycle and motility (García et al., 2014). In non-phagocytic
cells, the internalization of L. monocytogenes is mediated by
one of two invasins, depending on the polarization of the
cell. In polarized epithelial cells, invasin InlA uses molecule
E-cadherin in junctional sites. However, for internalization in
non-polarized cells, L. monocytogenes utilizes InlB to interact
with GAGs through the hepatocyte growth factor receptor Met;
the formation of this complex promotes the endocytosis of the
receptor with the bound bacterium (Pizarro-Cerdá and Cossart,
2006).
Although S. aureus is a member of the normal human
microbiota, it is a common cause of infections affecting different
parts of the body (Barlett and Park, 2010). The adherence of
the bacterium to the intestinal epithelium and its internalization
involve various mechanisms. One is mediated by two bacterial
fibronectin binding proteins (FnBPs) that interact with the
β1 integrin (Hauck and Ohlsen, 2006; Hess et al., 2006).
An alternative mechanism involves the interaction between a
heparin-binding protein and HSPGs, mainly syndecan-1 (García
et al., 2014), which allows adherence and internalization via non-
professional phagocytes in a fibronectin independent way (Hess
et al., 2006).
A group B streptococci, S. agalactiae, occasionally colonizes
mucosal surfaces of the human gastrointestinal tract. This
pathogen is potentially highly invasive and dangerous in infants,
in the elderly and in diabetic patients. As in cases of its adhesion
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and crossing of the BBB, the bacterium uses ACP to interact with
HSPGs, mainly syndecan-1, for adherence and entrance into cells,
through an actin-dependent mechanism (Kamhi et al., 2013).
SEXUAL INFECTIOUS DISEASES
Sexually transmitted infections can be caused by more than
30 different bacteria, viruses, and parasites (World Health
Organization, 2013). One of the most important sexually
transmitted diseases is gonorrhea, caused by Neisseria
gonorrhoeae. The bacterium employs diverse strategies for
adherence to cell surfaces, including pili and several Opa
adhesins, such as OpaA, which uses syndecan-1 and -4 as
receptors (García et al., 2014). Following the interaction with
OpaA, the cytoplasmic domains of syndecans trigger intracellular
signaling cascades, activating phosphatidylcholine-specific
phospholipase C and the acid sphingomyelinase, which leads to
ceramide formation. Ceramide mediates in the reorganization
of actin and endocytosis of gonococci. The syndecan-Opa
complexes can also induce protein kinase C activation via an
integrin-mediated mechanism, through binding to the serum
ECM proteins fibronectin and vitronectin (Kühlewein et al.,
2006).
Another common pathogen in sexual disseases is Chlamydia
trachomatis. The bacterium has diverse serovars, which cause
different diseases: serovars A-C cause trachoma; serovars D-K
are involved in sexually transmitted infections and serovars L1,
L2, and L3 cause lymphogranuloma venereum. The individual
serovars have different strategies for adhesion and colonization
(Becker, 1996). C. trachomatis is able to use diverse binding
mechanisms, including some that involve direct interaction with
HS on cells. Depending on the serovar, the degree of HS
involvement varies, it being essential for serovar L2 binding
but not for serovar E (Taraktchoglou et al., 2001). Additionally,
C. trachomatis is able to adhere to and enter cells by indirect
ways due to the interaction between its EB infectious forms and
fibroblast growth factor 2 (FGF2; Kim et al., 2012). The complex
thus formed interacts with the FGF2 receptor, which is locally
activated and mediates in EB internalization into cells. The EB-
FGF2 complex may involve synergistic interactions with the EB
membrane bacterial protein OmcB, which also interacts with HS
from the cell surface (Fechtner et al., 2013). The internalization of
bacteria increases the production of FGF2, triggering a positive
feedback which upregulates the infection. FGF2 may also play
additional roles in enhancing pathogenesis by potentiation of
inflammatory response, inhibition of apoptosis and regulation of
gene expression (Kim et al., 2012).
OCULAR INFECTIOUS DISEASES
There is a wide range of non-specific pathogens which are able
to infect certain areas of the eye, mainly conjunctiva, lid, and
cornea. The most common external ocular infections are caused
by bacteria, which mainly interact with HS chains as receptors
(Armstrong, 2000). Most keratitis are caused by S. aureus and
P. aeruginosa. As described above, both interact with HSPGs from
injured epithelium, a requirement for corneal invasion.
The adherence of S. aureus to corneal epithelium takes place
via collagen-binding adhesin and FnBPs A and B, which interact
with collagen and fibronectin, respectively (Armstrong, 2000).
Syndecan-1 is not involved in the initial attachment, although
S. aureus induces its shedding via α- and β-toxin (Barlett and
Park, 2010; Hayashida et al., 2011). Syndecan-1 ectodomains
increase pathogenicity and the potential for bacterial survival
by interacting with neutrophils, whose antibacterial function
is thus inhibited. The shedding of syndecan-1 also affects the
inflammatory process by generating gradients of quimioatractors
(Hayashida et al., 2011).
Severe keratitis and central corneal ulcers are caused by
P. aeruginosa infections (Fleiszig and Evans, 2002). The initial
attachment is mediated by surface structures such as pili and
polysaccharides, which mediate biofilm formation over the
epithelium and on contact lenses. Extended contact lens wearing
increases bacterial adherence to corneal epithelium (Fleiszig
and Evans, 2002). The bacterium is not only able to adhere
to cell surfaces, but it also interacts with perlecan from ECM
(Willcox, 2007). As was described earlier, the bacterium is able to
produce several exoproducts that degrade PGs and produce tissue
injury by degradation of basement membranes and the ECM,
promoting bacterial virulence and invasion both individually and
via quorum-sensing (Twining et al., 1993; O’Callaghan et al.,
1996; Chen and Hazlett, 2001). The bacterium P. aeruginosa also
induces the production of host exoproducts that contribute to
corneal damage and to an excessive activation of the host defense
system (Twining et al., 1993).
GLYCOSAMINOGLYCANS AS
THERAPEUTIC TARGETS
The increase in the emergence of antibiotic resistant bacterial
pathogens has limited the efficacy of existing treatments in
infections. New therapies which can supplement or replace old
treatments avoiding the selective pressures that lead to bacterial
resistance should be investigated and developed urgently. GAGs
have been widely explored and used as therapeutic agents in
diverse biomedical treatments. This broad application of GAGs is
due to their involvement in multiple physiological processes such
as coagulation, thrombosis, inflammation, cancer, angiogenesis,
cell differentiation, tissue repair, and microbial infections (San
Antonio and Iozzo, 2001).
The therapeutic applications of certain GAGs are well-known,
including the use of HA in various joint disorders and plastic
surgery (Kogan et al., 2007), of HP as an anticoagulant and anti-
inflammatory agent (Young, 2008), and of CS in the treatment
of osteoarthritis (Clegg et al., 2006). In the last few years,
GAG molecules have begun to be used as drug delivery agents
in nanomedicine. GAGs interact electrostatically with different
compounds or biologics used for therapeutic purposes thanks to
their strong negative charge. The drugs are delivered systemically
or locally to treat a variety of pathological conditions, including
cancer, glaucoma, wounds, and burns (Misra et al., 2015).
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The increased understanding of the structure–function
relationship of GAGs has made possible the design of new
compounds with a potential therapeutic role in a variety of
diseases (Raman et al., 2005; Gandhi and Mancera, 2008).
Some analogs and antagonists of these molecules, with suitable
charge and conformation, have already been developed and used
to affect some GAG functions, including anticoagulants, anti-
inflammatories, antimetastatics, and also to interfere with their
ability to interact with growth factors, proteases, and different
host defense molecules, such as neutrophils, proinflammatory
molecules, and antimicrobial peptides (Rusnati et al., 2005;
Rusnati and Urbinati, 2009; Harris et al., 2014). The use of GAG
based-molecules in the field of cancer is particularly interesting,
several compounds having already entered the clinic, and one of
them (PI-88) currently being in phase III trials (Ferro et al., 2007).
Since different GAGs mediate interactions with pathogens, the
characterization of the different roles played by these molecules in
several infectious pathologies is essential in order to design new
therapeutic molecules based on these polysaccharides which may
interfere in the establishment of microorganisms.
A layer of extracellular GAGs covers the healthy urothelium;
these molecules attract water, creating a chemical barrier that
protects against infections. During urinary tract infections the
layer of GAGs becomes damaged. The restoration of this layer
with GAGs supplied exogenously has been shown to play a
protective role against recurrent infections and inflammatory
factors (Yazawa, 2014). Other experiments have demonstrated
that intravesical therapy using some GAGs, specifically HA
and CS, was more effective than antibiotic therapy in reducing
recurrent episodes of infections in the urinary tract (Torella
et al., 2013). Natural or synthetic GAGs can be used as
prophylactic agents in treatments for recurrent urinary tract
infections, and even as adjunctive therapy with classic anti-
infective treatments.
Hyaluronic acid has also been useful in different therapeutic
aplications, such as in the treatment of chronic bronchitis. The
treatment of such patients with HA led to a reduced number
of acute episodes than in patients treated with a placebo. These
experiments suggest that HA reduces aggravation in patients with
chronic bronchitis and may help to decrease the use of antibiotics
in their therapies, diminishing the risk of generating antibiotic
resistance. The investigators involved in this trial proposed that
HA possibly enhances host cellular defense mechanisms (Venge
et al., 1996; Souza-Fernandes et al., 2006).
Therapeutic GAG-like molecules can come from different
natural sources, including mammalian tissues, non-mammalian
origins such as invertebrates, and synthetic GAG mimetics.
These molecules can act both as agonist or antagonist either
by interfering with endogenous GAGs or by forming complexes
with protein ligand and/or receptors (Rudd et al., 2012;
Pomin, 2015). The possible role of GAG analogs in inhibiting
pathogen interaction has been widely studied, especially in virus
attachment and dissemination.
Heparin derivatives and heparin-mimicking molecules are
called heparinoids, and they have been used in many therapeutic
applications as inhibitors of HS-protein interactions. Fucoidans
are heparinoids obtained from marine brown algae. For the
past decade fucoidans isolated from different species have been
extensively studied due to their wide variety of biological
activities, but their potent anticoagulant action is by far the
most widely investigated. These molecules also have different
anti-infective activities, including antiviral activity against a wide
range of viruses via receptor entry blocking or interference with
replicative processes (Li et al., 2008). Various experiments have
demonstrated that fucoidans also have antiparasitic activities
against Toxoplasma gondii, Plasmodium, and Leishmania.
Moreover, recent in vitro and in vivo studies have related
treatment with fucoidans with prevention of infection by
H. pylori through the inhibition of adhesion to mucosal surfaces
(Fitton, 2011). All these results show the potential of these
molecules to be used as prophylaxis measures.
Another heparinoid analog of HS is suramin, which also
presents different therapeutic activities, mainly antiangiogenic,
antiviral – through its inhibition of the reverse transcriptase
of several retroviruses (Wang et al., 2014), and antiparasite
(McGeary et al., 2008). The effect of suramin against pathogenic
bacteria has also been analyzed in different studies and it has been
found to be able to produce non-specific antibacterial resistance
against Mycobacterium bovis and L. monocytogenes through
macrophage activations (Brandely et al., 1986). This analog is also
a potent inhibitor of RecA protein of M. tuberculosis, the protein
that is responsible for the development of antibiotic resistance
(Nautiyal et al., 2014).
Heparosan, produced and found in the capsule of some
pathogenic bacteria such as Escherichia coli K5 and Pasteurella
multocida, is a molecule whose structure is similar to unmodified
natural HS. Heparosan can be modified by chemical or enzymatic
methods, thereby creating new derivatives capable of affecting
different processes, such as molecules that display antiviral
activity in vitro, especially against the human immunodeficiency
virus (HIV), herpes simplex virus, and human papilloma virus
(Li et al., 2013). Both HP and heparosan are able to block the
adhesion of pathogenic E. coli, Pasteurella multocida, S. aureus
to enterocytes, while Lactobacillus rhamnosus adherence is not
altered. In addition, treatment with probiotics supplemented
with heparosan has been suggested as a preventive treatment for
infections (Chen et al., 2012).
Chondroitin derivatives have also been found in nature, such
as fucosylated CS (FucCS) from sea cucumber species. This
molecule possesses diverse activities, such as anti-coagulant, anti-
thrombotic, anti-inflammatory, and anti-cancer actions. FucCS is
also able to block HIV virus entry into cells (Huang et al., 2013)
and P. falciparum cytoadherence to endothelial cells (Bastos et al.,
2014).
Other GAG analogs displaying a suitable charge and
conformation can interfere with the electrostatic interaction
of the GAGs themselves with host defense molecules. The
bactericidal activity of some cationic antimicrobial peptides,
such as LL-37, is disabled when the peptides bind to
GAGs. The electrostatic interaction of LL-37 with these
molecules can be disrupted by nebulized hypertonic saline
treatment, included in the therapy against airway mucus of
CF patients. The release of LL-37 results in a restoration
of the peptide antimicrobial activity (Reeves et al., 2011).
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In addition to molecules of various natural origins,
knowledge of the relation between the structure and function
of GAGs has allowed the design and development of various
families of synthetic derivatives for different therapeutic
purposes. Semi-synthetic glycosaminoglycan ethers (SAGEs)
are derived from sulfation and alkylation of HA; different
SAGEs can be used in the treatment and prevention of
different pathologies, including cancer (Prestwich and Kennedy,
2011), or different ophthalmic therapies (Prestwich et al.,
2012). SAGEs can also play a role in infection treatments;
gingivitis and periodontitis are initiated by chronic bacterial
infections caused among others by Porphryomonas gingivalis.
This therapy can be a major advantage compared to treatment
with antibiotics which may lead to the generation of resistant
bacteria.
ReGeneraTing Agents (RGTAs) are synthetic HS mimics
resistant to digestion with multiple endoglycanases such as
heparanase, chondroitinase, hyaluronidase, and dextranase.
They are able to interfere in the interaction of GAGs with
different ligands, including various growth factors such as
FGF1, FGF2, and VEGF, and can play an important role
in wound regeneration. CACIPLIQ20r (OTR3, Paris, France)
is an RGTA member specifically designed to restore the
damaged ECM in chronic wounds. Indirectly, these molecules,
based on GAGs, may be useful in preventing infections
in open wounds and thus reducing the time of exposure
to pathogens (Barbier-Chassefière et al., 2009; Ikeda et al.,
2011).
Different monosaccharides have been chemically modified
in order to interfere with GAG biosynthesis, chain elongation,
or sulfation. One of them is peracetylated 6-fluoro-N-
acetylgalactosamine [6F-GalNAc (Ac3)], which can potentially
inhibit 6-O sulfation of GAG chains. As described above, the
sulfation pattern is essential for interaction with various ligands
as well as for pathogen adhesion. Another of these sugars, 6F-
N-acetyl-D-galactosamine, is an inhibitor of GAG biosynthesis,
which may affect the adhesion of many ligands, including bacteria
(van Wijk et al., 2015).
Different antagonists of GAGs have also been designed for
therapeutic purposes. Surfen, bis-2-methyl-4-amino-quinolyl-
6-carbamide, is an antagonist of HS first described in 1938
as an excipient for the production of depot insulin. This
molecule binds electrostatically to sulfated GAGs, competing
in their interaction with different molecules, including FGF2,
VEGF or glycoprotein D and, consequently, altering different
processes, such as anticoagulant activity, cell adhesion to
fibronectin, and viral infection by HIV-1 (Schuksz et al.,
2008).
CONCLUSION
The report on antimicrobial resistance made by the
WHO in 2014 emphasizes a previously known problem
that has increased significantly in recent years: bacterial
resistance to antibiotics. PGs and GAGs present unique
characteristics that allow them to play essential roles in the
interaction between bacterial pathogens and host cells. The
characterization of GAG-pathogen interactions has allowed
the development of certain therapeutic molecules which are
able to fight different infections. Further studies will lead
to new therapies capable of more efficiently interfering with
or blocking infections, helping to overcome antimicrobial
resistance.
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